Published in Anticancer Res on September 01, 2009
Expression of vitamin D receptor decreases during progression of pigmented skin lesions. Hum Pathol (2011) 1.38
Vitamin D and cancer. Front Endocrinol (Lausanne) (2012) 1.15
Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial. J Clin Oncol (2011) 1.08
Vitamin D receptor (VDR) polymorphisms and skin cancer: A systematic review. Dermatoendocrinol (2011) 1.02
Decreased VDR expression in cutaneous melanomas as marker of tumor progression: new data and analyses. Anticancer Res (2014) 0.93
Pre-diagnostic circulating vitamin D and risk of melanoma in men. PLoS One (2012) 0.90
The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms. Exp Dermatol (2010) 0.89
Vitamin D and melanoma incidence and mortality. Pigment Cell Melanoma Res (2012) 0.87
Vitamin D in cutaneous carcinogenesis: part II. J Am Acad Dermatol (2012) 0.86
Vitamin D and skin cancer. Photochem Photobiol (2014) 0.85
Prevalence of serum vitamin D deficiency and insufficiency in cancer: Review of the epidemiological literature. Exp Ther Med (2011) 0.85
Vitamin D and colon cancer. World J Gastrointest Oncol (2014) 0.85
An inherited variant in the gene coding for vitamin D-binding protein and survival from cutaneous melanoma: a BioGenoMEL study. Pigment Cell Melanoma Res (2013) 0.84
Low serum 25-hydroxyvitamin d concentrations are associated with increased risk for melanoma and unfavourable prognosis. PLoS One (2014) 0.83
Vitamin D and melanoma. Dermatoendocrinol (2013) 0.82
Serum 25-hydroxyvitamin D3 levels and vitamin D receptor variants in melanoma patients from the Mediterranean area of Barcelona. BMC Med Genet (2013) 0.81
Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. J Clin Oncol (2016) 0.81
Vitamin D deficiency at melanoma diagnosis is associated with higher Breslow thickness. PLoS One (2015) 0.80
Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: a placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D). BMC Cancer (2014) 0.80
Genetic variants in the vitamin D pathway genes VDBP and RXRA modulate cutaneous melanoma disease-specific survival. Pigment Cell Melanoma Res (2016) 0.79
Vitamin D in the cancer patient. Curr Opin Support Palliat Care (2013) 0.78
From the bench to emerging new clinical concepts: Our present understanding of the importance of the vitamin D endocrine system (VDES) for skin cancer. Dermatoendocrinol (2011) 0.78
Why vitamin D for cancer patients? Ecancermedicalscience (2009) 0.77
Skin changes after bariatric surgery. An Bras Dermatol (2015) 0.75
Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma. Oncotarget (2016) 0.75
Serum level of vitamin D3 in cutaneous melanoma. Einstein (Sao Paulo) (2015) 0.75
Has Vitamin D Had Its "Time In The Sun" For Melanoma? J Clin Aesthet Dermatol (2016) 0.75
Antiproliferative Effects of 1α-OH-vitD3 in Malignant Melanoma: Potential Therapeutic implications. Sci Rep (2017) 0.75
The impact of vitamin D pathway genetic variation and circulating 25-hydroxyvitamin D on cancer outcome: systematic review and meta-analysis. Br J Cancer (2017) 0.75
Nucleotide Excision Repair and Vitamin D-Relevance for Skin Cancer Therapy. Int J Mol Sci (2016) 0.75
Vitamins and Melanoma. Cancers (Basel) (2015) 0.75
A protocol for prospective studies of 25-hydroxyvitamin D, leptin and body mass index in relation to cutaneous melanoma incidence and survival. BMJ Open (2017) 0.75
Vitamin D status and risk for malignant cutaneous melanoma: recent advances. Eur J Cancer Prev (2017) 0.75
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
Binding of non-native protein to Hsp25 during heat shock creates a reservoir of folding intermediates for reactivation. EMBO J (1997) 2.92
Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol (2001) 2.58
"False-positive" anti-neutrophil cytoplasmic antibodies in HIV infection. Lancet (1990) 1.94
Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ (2006) 1.83
Enhanced blood coagulation and fibrinolysis in mice lacking histidine-rich glycoprotein (HRG). J Thromb Haemost (2005) 1.72
Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer (2005) 1.66
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol (2014) 1.63
Melanocytes as "sensory" and regulatory cells in the epidermis. J Theor Biol (1993) 1.55
Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation (2001) 1.54
Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res (2001) 1.53
Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin Chem (2001) 1.50
Phenotypic and genotypic characteristics of a cell line from a squamous cell carcinoma of human skin. J Natl Cancer Inst (1982) 1.49
Plasma homocysteine levels & 677C-->T methylenetetrahydrofolate reductase gene polymorphism in patients with coronary artery disease of different severity. Indian J Med Res (2008) 1.47
Human mast cells produce IL-8. J Immunol (1993) 1.44
Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma. Onkologie (2004) 1.43
Preservation of morphological, functional, and karyotypic traits during long-term culture and in vivo passage of two human skin squamous cell carcinomas. Cancer Res (1983) 1.42
Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol (1999) 1.40
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer (2013) 1.38
Growth and differentiation characteristics of transformed keratinocytes from mouse and human skin in vitro and in vivo. J Invest Dermatol (1983) 1.36
Self-funding takes command of group health market. Bus Insur (1986) 1.35
Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis (1999) 1.30
Detection of a human melanoma-associated antigen, p97, in histological sections of primary human melanomas. Int J Cancer (1982) 1.29
Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother (2000) 1.27
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res (2003) 1.24
Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci U S A (2001) 1.24
The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer (1999) 1.22
Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J Clin Oncol (1997) 1.20
Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol (1997) 1.20
Deficient IL-12p70 secretion by dendritic cells based on IL12B promoter genotype. Genes Immun (2004) 1.18
Biomarkers in melanoma. Ann Oncol (2009) 1.17
Drug-resistance in human melanoma. Int J Cancer (2001) 1.15
[Management of pyoderma gangrenosum. An update on clinical features, diagnosis and therapy]. Hautarzt (2010) 1.15
Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J Cell Physiol (2007) 1.14
Metabolism of vitamin D3 in the placental tissue of normal and preeclampsia complicated pregnancies and premature births. Clin Exp Obstet Gynecol (2007) 1.14
Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis (2000) 1.14
Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival. Br J Cancer (2002) 1.11
Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab (2012) 1.10
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer (2011) 1.10
Identification and characterization of MTR1, a novel gene with homology to melastatin (MLSN1) and the trp gene family located in the BWS-WT2 critical region on chromosome 11p15.5 and showing allele-specific expression. Hum Mol Genet (2000) 1.09
Small molecules and targeted therapies in distant metastatic disease. Ann Oncol (2009) 1.08
Purpose and structure of strategic plans for information management in hospitals. Stud Health Technol Inform (2000) 1.07
Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer (2001) 1.06
Symptom profile and risk factors of anaphylaxis in Central Europe. Allergy (2012) 1.05
Lichen striatus and blaschkitis: reappraisal of the concept of blaschkolinear dermatoses. Br J Dermatol (2010) 1.05
Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer (2001) 1.05
Human dendritic cells infected by Listeria monocytogenes: induction of maturation, requirements for phagolysosomal escape and antigen presentation capacity. Eur J Immunol (2000) 1.04
Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer (2002) 1.03
DFNA5 (ICERE-1) contributes to acquired etoposide resistance in melanoma cells. FEBS Lett (2001) 1.03
Dose-dependent severe cutaneous reactions to imatinib. Br J Cancer (2003) 1.03
Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer (2001) 1.02
[The "Stade éphélide" of precancerous melanosis. A comparative clinical, histopathological, and electron microscopical study]. Arch Dermatol Forsch (1970) 1.01
Clusterin and DNA repair: a new function in cancer for a key player in apoptosis and cell cycle control. J Mol Histol (2006) 1.00
Sperm morphology assessment using strict criteria and male fertility under in-vivo conditions of conception. Hum Reprod (1996) 0.99
Seroprevalence of parvovirus B19 in the German population. Epidemiol Infect (2008) 0.98
CD4+CD7- leukemic T cells from patients with Sézary syndrome are protected from galectin-1-triggered T cell death. Leukemia (2002) 0.98
Cognitive deficits in spinocerebellar ataxia 2. Brain (1999) 0.98
Cutaneous large B-cell lymphoma of the leg masquerading as a chronic venous ulcer. Br J Dermatol (2002) 0.97
Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs. Int J Cancer (2000) 0.96
The polymerase chain reaction. Method and applications in dermatopathology. Am J Dermatopathol (1993) 0.96
Substance use and sexual risk behaviour among HIV-positive men who have sex with men in specialized out-patient clinics. HIV Med (2012) 0.96
Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells. J Immunol (1998) 0.96
Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. J Clin Pathol (2001) 0.96
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer (2010) 0.96
Up-regulation of keratin 17 expression in human HaCaT keratinocytes by interferon-gamma. J Invest Dermatol (1995) 0.96
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. Ann Oncol (2006) 0.96
Mutational spectrum of NSDHL in CHILD syndrome. J Med Genet (2005) 0.95
Role of homocysteine, cystathionine and methylmalonic acid measurement for diagnosis of vitamin deficiency in high-aged subjects. Eur J Clin Invest (2000) 0.95
Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther (1998) 0.95
Dermal fibroblasts sustain proliferation of activated T cells via membrane-bound interleukin-15 upon long-term stimulation with tumor necrosis factor-alpha. J Invest Dermatol (2001) 0.95
[First exchange of experiences concerning the H1N1 pandemic in Germany 2009/2010: report on a workshop held March 22-23, 2010, in Berlin]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2010) 0.93
Assignment of Tangier disease to chromosome 9q31 by a graphical linkage exclusion strategy. Nat Genet (1998) 0.93
Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen. Int J Cancer (2000) 0.93
Polidocanol foam sclerotherapy is a new and effective treatment for post-operative lymphorrhea and lymphocele. J Eur Acad Dermatol Venereol (2010) 0.92
Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance. Br J Cancer (2000) 0.91
Categorical speech perception in cerebellar disorders. Brain Lang (1997) 0.91
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Ann Oncol (2008) 0.91
Preparing strategic information management plans for hospitals: a practical guideline SIM plans for hospitals: a guideline. Int J Med Inform (2005) 0.91
Assessment of gonadal maturation by evaluation of spermaturia. Arch Dis Child (1990) 0.91
SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma. Br J Dermatol (2004) 0.91
Analysis of 1,25-dihydroxyvitamin D(3) receptors (VDR) in basal cell carcinomas. Am J Pathol (1999) 0.91
VDR microRNA expression and epigenetic silencing of vitamin D signaling in melanoma cells. J Steroid Biochem Mol Biol (2010) 0.90
Clinical relevance of sperm morphology assessment using strict criteria and relationship with sperm-mucus interaction in vivo and in vitro. Fertil Steril (1995) 0.90
Functional HLA-DM on the surface of B cells and immature dendritic cells. EMBO J (2000) 0.90
Ultraviolet light exposure, pigmentary traits and the development of melanocytic naevi and cutaneous melanoma. A case-control study of the German Central Malignant Melanoma Registry. Acta Derm Venereol (1997) 0.90
Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br J Cancer (1998) 0.90
Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases. Z Kardiol (2004) 0.90
Malignancies of the uterine corpus and immunoreactivity score of the DNA "mismatch-repair" enzyme human Mut-S-homologon-2. J Histochem Cytochem (1999) 0.89
CD4(+)CD7(-) T cells compose the dominant T-cell clone in the peripheral blood of patients with Sézary syndrome. J Am Acad Dermatol (2001) 0.89